South America Viral Vectors Plasmid DNA Manufacturing Market

ID: MRFR/HC/50129-HCR
200 Pages
Rahul Gotadki
Last Updated: March 28, 2026
South America Viral Vectors and Plasmid DNA Manufacturing Market Research Report: Size, Share, Trend Analysis By Vector Type (Plasmid DNA, Viral Vector, Non-viral Vector), By Disease Type (Cancer, Genetic Disorder, Infectious Disease), By Applications (Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, Research), By Workflow (Upstream Processing, Downstream Processing), By End-User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035
South America Viral Vectors Plasmid DNA Manufacturing Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)11.99%
2024 Market Size$ 40 Million
2025 Market Size$ 45.3 Million
2035 Market Size$ 139 Million
Key Players
Sangamo Therapeutics
Novartis
Boehringer Ingelheim
Aldevron
Cobra Biologics
Viva Biotech
Trends
  • Rising Demand for Gene Therapy
  • Strengthening Regulatory Frameworks
  • Collaborative Research Initiatives
Opportunities
  • Supportive Government Policies
  • Increasing Investment in Biotechnology
  • Growing Prevalence of Genetic Disorders
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Gene Therapy
      2. 4.1.2 Vaccines
      3. 4.1.3 Oncology
      4. 4.1.4 Infectious Diseases
      5. 4.1.5 Genetic Disorders
    2. 4.2 Healthcare, BY End Use (USD Million)
      1. 4.2.1 Pharmaceutical Companies
      2. 4.2.2 Biotechnology Companies
      3. 4.2.3 Research Institutions
      4. 4.2.4 Academic Institutions
    3. 4.3 Healthcare, BY Type of Vector (USD Million)
      1. 4.3.1 Adenoviral Vectors
      2. 4.3.2 Lentiviral Vectors
      3. 4.3.3 Adeno-Associated Viral Vectors
      4. 4.3.4 Retroviral Vectors
    4. 4.4 Healthcare, BY Scale of Production (USD Million)
      1. 4.4.1 Small Scale
      2. 4.4.2 Medium Scale
      3. 4.4.3 Large Scale
    5. 4.5 Healthcare, BY Technology (USD Million)
      1. 4.5.1 Transfection
      2. 4.5.2 Viral Packaging
      3. 4.5.3 Plasmid Purification
      4. 4.5.4 Cell Culture
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Sangamo Therapeutics (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Boehringer Ingelheim (DE)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Aldevron (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Cobra Biologics (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Viva Biotech (CN)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Genomatix (DE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Virovek (BR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 OncoOne (CH)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY END USE
    4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY TYPE OF VECTOR
    5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY SCALE OF PRODUCTION
    6. 6.6 SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY TYPE OF VECTOR, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY TYPE OF VECTOR, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY SCALE OF PRODUCTION, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY SCALE OF PRODUCTION, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY END USE, 2026-2035 (USD Million)
      3. 7.2.3 BY TYPE OF VECTOR, 2026-2035 (USD Million)
      4. 7.2.4 BY SCALE OF PRODUCTION, 2026-2035 (USD Million)
      5. 7.2.5 BY TECHNOLOGY, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South America South America Viral Vectors Plasmid DNA Manufacturing Market Segmentation

South America Viral Vectors Plasmid DNA Manufacturing Market By Application (USD Million, 2026-2035)

  • Gene Therapy
  • Vaccines
  • Oncology
  • Infectious Diseases
  • Genetic Disorders

South America Viral Vectors Plasmid DNA Manufacturing Market By End Use (USD Million, 2026-2035)

  • South America Viral Vectors Plasmid DNA Manufacturing Market Companies
  • Biotechnology Companies
  • Research Institutions
  • Academic Institutions

South America Viral Vectors Plasmid DNA Manufacturing Market By Type of Vector (USD Million, 2026-2035)

  • Adenoviral Vectors
  • Lentiviral Vectors
  • Adeno-Associated Viral Vectors
  • Retroviral Vectors

South America Viral Vectors Plasmid DNA Manufacturing Market By Scale of Production (USD Million, 2026-2035)

  • Small Scale
  • Medium Scale
  • Large Scale

South America Viral Vectors Plasmid DNA Manufacturing Market By Technology (USD Million, 2026-2035)

  • Transfection
  • Viral Packaging
  • Plasmid Purification
  • Cell Culture

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.